HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hammond, P. J. Articles by Bloom, S. R. Search for Related Content PubMed PubMed Citation Articles by Hammond, P. J. Articles by Bloom, S. R.

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) are hypothalamic peptides sharing considerable sequence homology which are postulated to be hypophysiotrophic releasing factors. When infused into man, PACAP has no effect on anterior pituitary hormone levels, while VIP causes a significant increase in circulating prolactin concentrations. However, PACAP has recently been shown to augment the release of LH and FSH in response to LHRH in rat anterior pituitary cell culture. In order to ascertain if either peptide has a similar effect in man, PACAP and VIP were infused at 3·6 pmol/kg per min into six healthy male volunteers, and an LHRH test was performed 30 min after the infusion was commenced. Infusion of PACAP did not alter the gonadotrophin response to LHRH significantly. However, VIP augmented the release of LH significantly, both during the infusion and for 30 min thereafter, although there was no effect on FSH release. Thus VIP, but not PACAP, potentiates the release of LH after LHRH injection in man.

Journal of Endocrinology (1993) 137, 529–532

This article has been cited by other articles:

				A. Lacombe, V. Lelievre, C. E Roselli, J.-M. Muller, J. A Waschek, and E. Vilain Lack of vasoactive intestinal peptide reduces testosterone levels and reproductive aging in mouse testis J. Endocrinol., July 1, 2007; 194(1): 153 - 160. [Abstract] [Full Text] [PDF]

				A. Arimura, M. Li, and V. Batuman Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury Blood, January 15, 2006; 107(2): 661 - 668. [Abstract] [Full Text] [PDF]

				K. Filipsson, M. Kvist-Reimer, and B. Ahren The Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide and Islet Function Diabetes, September 1, 2001; 50(9): 1959 - 1969. [Abstract] [Full Text] [PDF]

				J. J. Evans Modulation of Gonadotropin Levels by Peptides Acting at the Anterior Pituitary Gland Endocr. Rev., February 1, 1999; 20(1): 46 - 67. [Abstract] [Full Text]

				K. Filipsson, K. Tornoe, J. Holst, and B. Ahren Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Insulin and Glucagon Secretion in Humans J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3093 - 3098. [Abstract] [Full Text] [PDF]